A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL‐1401O vs. EU‐trastuzumab and US‐trastuzumab

AIMS: Trastuzumab is a humanized monoclonal antibody that binds the human epidermal growth factor receptor 2 (HER2) oncoprotein and is an effective therapy for HER2‐overexpressing breast cancer. MYL‐1401O is a trastuzumab biosimilar. Here, we report results from a phase 1 study that investigated bio...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Clin Pharmacol
Autores principales: Waller, Cornelius F., Vutikullird, Apinya, Lawrence, Tracey E., Shaw, Andrew, Liu, Mark Shiyao, Baczkowski, Mark, Sharma, Rajiv, Barve, Abhijit, Goyal, Parag, Donnelly, Charles, Sengupta, Nilanjan, Pennella, Eduardo J.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6138509/
https://ncbi.nlm.nih.gov/pubmed/29926514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13689
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares